Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechXMAD:VYT +0.31%66 EV-to-EBITDA is 28.95 as of Aug. 17, 2026, which is 73% above its 10-year median of 16.74. GuruFocus rates XMAD:VYT with a GF Score™ of 66/100 and a GF Value™ of €5.65 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 401 Biotechnology companies, Vytrus Biotech ranks worse than 71.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vytrus Biotech's enterprise value is €120.36 Mil.
Vytrus Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €4.16 Mil. Therefore, Vytrus Biotech's EV-to-EBITDA for today is 28.95.
The historical rank and industry rank for Vytrus Biotech's EV-to-EBITDA or its related term are showing as below:
XMAD:VYT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.83 Med: 16.74 Max: 39.33
Current: 28.95
During the past 8 years, the highest EV-to-EBITDA of Vytrus Biotech was 39.33. The lowest was 8.83. And the median was 16.74.
XMAD:VYT's EV-to-EBITDA is ranked worse than 71.32% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs XMAD:VYT: 28.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vytrus Biotech's PE Ratio (TTM) for today is calculated as:
Vytrus Biotech's share price for today is €16.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vytrus Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.401.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vytrus Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vytrus Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's EV-to-EBITDA falls into.
Vytrus Biotech's current Enterprise Value is €120.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vytrus Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €4.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (XMAD:VYT) has a EV-to-EBITDA of 28.95 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vytrus Biotech. This is 73% above median its historical median of 16.74. Over the past decade, Vytrus Biotech's EV-to-EBITDA has ranged from 8.83 to 39.33. According to the industry distribution chart, Vytrus Biotech ranks #286 out of 401 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Vytrus Biotech's EV-to-EBITDA too high?
Vytrus Biotech's current EV-to-EBITDA of 28.95 is 73% above median its 10-year median of 16.74. Over the past 10 years, this metric has ranged from a low of 8.83 to a high of 39.33. The Biotechnology industry median EV-to-EBITDA is 13.80. Vytrus Biotech's value of 28.95 is 109.8% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #286 out of 401 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #286 out of 401 companies for EV-to-EBITDA. This places Vytrus Biotech in the lower half of its industry. The industry median EV-to-EBITDA is 13.80. Vytrus Biotech's value of 28.95 is 109.8% above this benchmark. Historically, Vytrus Biotech's own EV-to-EBITDA has ranged from 8.83 to 39.33 over the past decade. While the company's 10-year median is 16.74 vs. the industry median of 13.80, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current EV-to-EBITDA of 28.95 is 109.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vytrus Biotech. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current EV-to-EBITDA is 28.95, which is 73% above median its own 10-year median of 16.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.65, compared to a current price of €16.20 — trading 186.7% above its estimated fair value. The current EV-to-EBITDA is 28.95, which is 73% above median its 10-year median of 16.74 and 109.8% above the Biotechnology industry median of 13.80. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current EV-to-EBITDA is 28.95 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €16.20 is trading 186.7% above its estimated GF Value™ of €5.65.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
EV-to-EBITDA: 28.95 (73% above median its 10-year median of 16.74)
GF Value™: €5.65 vs. price of €16.20 (186.7% above fair value)
Industry Position: 109.8% above the Biotechnology median (#286 of 401)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score
Get the complete analysis for XMAD:VYT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
